A drug developer that discovers and develops cancer drug candidates with its Chemiverse AI platform.
01
Products & pipeline
PHI-101 (rasmotinib)
Phase 1
A candidate for FLT3-mutated acute myeloid leukaemia that completed a global Phase 1 in relapsed or refractory patients, reporting a 50.0% composite complete remission rate and 66.7% objective response rate in evaluable Phase 1b patients.
PHI-501
Phase 1
A solid-tumour candidate that inhibits BRAF and DDR1/2, in a Korean Phase 1 trial for patients with BRAF, KRAS or NRAS mutations at Severance, Samsung Medical Center and Kyungpook National University Chilgok Hospital.
Chemiverse
Technology platform
The company's in-house AI drug discovery platform, used for candidate discovery and indication expansion (DeepRECOM module).
02
Recent developments
Completion reported
Attended BIO-Europe 2026 for licensing and co-development talks on its cancer candidates.
Completion reported
Began first patient dosing in the Korean Phase 1 trial of PHI-501.
03
Experience in official career sources
Official role guide
Pharos iBio careers
Current availability unconfirmed
Observed 2026-11-18
Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.
Information from a role guide does not establish a current vacancy.
Sources & coverage 2
A brief based on selected official material, not an exhaustive product or vacancy list.